Vincristine and Irinotecan With or Without Temozolomide in Children and Adults With Refractory/Relapsed Rhabdomyosarcoma

RHABDOMYOSARCOMA Clinical Trial

— VIT-0910  

Official title:

International Randomized Phase II Trial of the Combination of Vincristine and Irinotecan With or Without Temozolomide (VI or VIT) in Children and Adults With Refractory or Relapsed Rhabdomyosarcoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01355445
• Other study ID #: VIT-0910
• Secondary ID: 2010-023135-42
• Status: Completed
• Phase: Phase 2
• Start date: January 2012
• Est. completion date: May 2019

Study information

• Verified date: September 2019
• Source: Centre Oscar Lambret
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an international open-label, randomized, multicenter phase II study of VIT and VI for the treatment of patients with recurrent or refractory rhabdomyosarcoma. The study will evaluate the safety and efficacy of these combinations in patients with recurrent or refractory rhabdomyosarcoma.

Description:

The dose of vincristine will be 1.5 mg/m² or 0.05 mg/kg for patient ≤ 10 kg (maximum 2 mg) and will be administered by direct intravenous infusion on day 1 and 8 of each course, before irinotecan.

The dose of irinotecan will be 50 mg/m²/d. Irinotecan will be given intravenously over 1 hour on days 1-5 of each course, one hour following the administration of temozolomide.

In the absence of any contraindication (ie known allergies), treatment with oral cefixime 8 mg/kg once daily (maximum daily dose 400 mg) is recommended and will be started 2 days before chemotherapy until day 7.

Temozolomide will be given according to the randomization. The starting dose of temozolomide will be 125 mg/m²/d. The dose of temozolomide will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience > grade 3 toxicity of any kind. Temozolomide will be given orally, on an empty stomach, on days 1 through 5 of each course.

Dose reductions and/or administration delays will be performed using specific predefined rules to accommodate individual patient tolerance of treatment and to maintain optimal dose intensity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: May 2019
• Est. primary completion date: June 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 50 Years

Eligibility

Inclusion Criteria:

• TUMOR CHARACTERISTICS :

• Histologically or cytologically confirmed diagnosis of rhabdomyosarcoma (RMS) (new biopsy recommended)

• Relapsed or refractory disease which has failed standard treatment approaches

• Patients must have measurable disease defined as lesions that can be measured in 3 dimensions by medical imaging techniques such as CT or MRI. Ascites, pleural fluid, bone marrow disease and lesions seen on Tc scintigraphy or PET scan only are not considered measurable for these patients

• PATIENT CHARACTERISTICS :

• Age > 6 months and = 50 years

• Karnofsky performance status (PS) 70-100% (for patients > 12 years of age) OR Lansky Play Score 70-100% (for patients = 12 years of age)

• Life expectancy = 12 weeks

• Adequate bone marrow function :

• Absolute neutrophil count = 1000/mm3; and = 500/mm3 in case of bone marrow disease

• Platelet count = 100000/mm3 ; and = 75000/mm3 in case of bone marrow disease (transfusion independent)

• Hemoglobin = 8.5 g/dl (transfusion allowed)

• Adequate renal function

• Serum creatinine = 1.5 X ULN for age

• If serum creatinine > 1.5 ULN, creatinine clearance (or radioisotope GFR) must be >70 ml/min/1.73 m²

• Adequate hepatic function :

• Total bilirubin = 1.5 times upper limit of normal (ULN) for age, except if the patient is known to have Gilbert's syndrome

• ALT and AST = 2.5 times ULN for age

• Negative pregnancy test in females with childbearing potential

• Fertile patients must use effective contraception

• No active > grade 2 diarrhea or uncontrolled infection

• No other malignancy, including secondary malignancy

• Patient affiliated with a health insurance system. Applicable for French patients only Written informed consent of patient and/or parents/guardians

• PRIOR or CONCURRENT THERAPY :

• More than 3 weeks since prior radiation therapy to the site of any progressive lesion that will be identified as a target lesion to measure tumor response

• At least 3 weeks since prior myelosuppressive therapy (6 weeks for nitrosourea. 2 weeks for vincristine, vinblastine, vinorelbine or low dose cyclophosphamide)

• No concurrent enzyme-inducing anticonvulsants (EIAC), including phenytoin, phenobarbital or carbamazepine

• No concurrent administration of any of the following: rifampicin, voriconazole,itraconazole, ketoconazole, aprepitant, St John's Wort

• No prior irinotecan or temozolomide administration

• Prior vincristine administration allowed

• Concurrent palliative radiation therapy to sites allowed other than the main measurable target

• Prior allo- or autologous SCT allowed

Exclusion Criteria:

• Inclusion criteria failure

• Concomitant anti-cancer treatment

• Know hypersensitivity to any component of study drugs or ingredients

• Pregnancy or breast feeding

• Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption

• Neuromuscular disorders (e.g. Charcot-Marie Tooth disease)

• Uncontrolled intercurrent illness or active infection

• Unavailable for medical follow-up (geographic, social or psychological reasons)

Related Conditions & MeSH terms

• RHABDOMYOSARCOMA

Intervention

Drug:
• Vincristine, Irinotecan
D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient = 10 kg) D1 to D5: Irinotecan 50 mg/m²/d, IV cycle / 21 days
• Vincristine, Irinotecan, Temozolomide
D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience > grade 3 toxicity of any kind) D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient = 10 kg) D1 to D5: Irinotecan 50 mg/m²/d, IV cycle / 21 days

Locations

Country	Name	City	State
France	CHU d'Amiens Picardie Site Sud	Amiens
France	Hôpital des Enfants, Groupe Hospitalier Pellegrin	Bordeaux
France	Centre Oscar Lambret	Lille cedex
France	Centre Léon Bérard	Lyon
France	CHU, Hôpital d'Enfants de la Timone	Marseille
France	Hôpital Arnaud de Villeneuve - CHU	Montpellier
France	CHU, Hôpital Mère enfants	Nantes
France	Hôpital Armand Trousseau	Paris
France	Institut Curie	Paris
France	Hôpital Jean Bernard	Poitiers
France	CHU Rennes - Hôpital Sud	Rennes
France	CHU St Etienne - Hôpital Nord	Saint-Etienne
France	Hôpital des enfants	Toulouse
France	CHRU	Tours
France	CHRU Hôpital d'Enfants	Vandoeuvre les Nancy
France	Institut Gustave Roussy	Villejuif

Sponsors (2)

Lead Sponsor	Collaborator
Centre Oscar Lambret	SFCE

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective tumour response and progression in each treatment arm.	The primary efficacy endpoint is defined as the proportion of patients who had a documented complete or partial tumour response occurring after the first 2 cycles of treatment which must be confirmed by a follow-up objective tumour assessment obtained within 4-5 weeks after the initial documentation.	at least 6 weeks (two cycles of treatment)
Secondary	To assess the duration of tumor response in each treatment arm	The duration of tumour response is defined as the time from first documentation of objective tumour response to the first objective or clinical documentation of progression	During all the study
Secondary	To determine the time to tumor progression in each treatment arm	The time to tumor progression: the time from the date of first treatment administration to the date of first objective or clinical documentation of tumour progression or death due to any cause	During all the study
Secondary	To assess the time to treatment failure in each treatment arm	The time to treatment failure is defined as the time from the date of first treatment administration to the first documentation of tumour progression, discontinuation of study treatment before one year, or death, whichever occurs first	Before 1 year
Secondary	To assess the overall survival in each treament arm	The overall survival is defined as the time from the date of first treatment administration to date of death	During all the study
Secondary	To assess the safety profile and tolerability in each treatment arm	Safety parameters include adverse events and haematology and blood chemistry assays.; Safety evaluations will include characterization of the frequency and severity of adverse events, complete blood cell counts with differential, serum chemistries and electrolytes, and change in weight and body surface area (BSA).	During all the study